Prevention of occlusion of cEnTral lInes for children with cancer: An implementation study. (17th August 2020)

• Record Type: Journal Article
• Authors: Ullman, Amanda J; Condon, Paula; Edwards, Rachel; Gibson, Victoria; Takashima, Mari; Schults, Jessica; Dean, Anna; Cattanach, Paula; Nicholls, Wayne; Osborne, Sonya; Rickard, Claire M; Cooke, Marie; Kleidon, Tricia
• Is Part Of: Journal of paediatrics and child health. Volume 56:Number 12(2020)
• Page Start: 1875
• Page End: 1884
• Publication Date: 2020-08-17
• Subjects: catheterization, peripheral -- central venous catheter -- implementation science -- neoplasm -- oncology nursing -- venous thrombosis; Children -- Health and hygiene -- Periodicals; Pediatrics -- Periodicals; 618.92
• DOI: 10.1111/jpc.15067
• Languages: English
• ISSNs: 1034-4810

Abstract

Abstract : Aim: Central venous access devices (CVADs) are vital medical devices to support the treatment of paediatric cancer; however, device occlusion is common, which disrupts treatment. This study aimed to improve the identification and management of CVAD occlusions in children with cancer, as well as to identify the demographic, clinical and device characteristics associated with increased risk for CVAD occlusion. Methods: A pre–post‐implementation study was conducted at a metropolitan paediatric oncology facility in Australia, using the Theoretical Domains Framework. Patients with a CVAD for anti‐cancer therapy were prospectively followed for occlusive events pre‐ and post‐ the implementation of clinical resources to support the identification and management of CVAD occlusive events. CVAD occlusion and management data were collected and compared pre‐ and post‐implementation. Risk factors for CVAD occlusion were described by mixed‐effects Poisson regression and incident rate ratios (IRR). Results: A total of 133 CVADs were inserted into 131 patients for a total of 6784 catheter days. The incidence of CVAD‐related occlusion pre‐implementation was 59.7 (95% confidence interval (CI) 51.4–69.0, per 1000 catheter days); compared to 31.6 (95% CI 26.4–37.6); P < 0.01) post‐implementation of clinical resources. In multivariate models, other than post‐implementation phases (IRR 0.51 (95% CI 0.32–0.81)), only neutropaenia significantly increased the risk of CVAD occlusion (IRR 2.14 (95% CI 1.15–3.97)). Conclusion: CVAD occlusions in paediatric oncology are common. The development and implementation of CVAD occlusion resources to guide the identification and management of occlusive episodes led to a significant decrease in occlusive events.